Webinar

Antitrust in Life Sciences #3 Generics: Pay-For-Delay, Patent Settlements, Reverse Payment, Price-Fixing & Market Allocation

3rd webinar of the 2nd « Antitrust in Life Sciences » Conference organised by Concurrences, in partnership with NERA Economic Consulting and White & Case, with Molly Herron (Lead Group Antitrust Counsel - ex-Americas, Novartis), Ginger Jin (Professor, University of Maryland), Christine Meyer (Chair, Intellectual Property Practice & Managing Director, NERA Economic Consulting) and Robert Milne (Partner, White & Case).

- Video: Available for Concurrences+ subscribers (see below)

- Audio: Available for Concurrences+ subscribers (see below)

- Synthesis: Available for Concurrences+ subscribers (see above)

- Transcript: Available for Concurrences+ subscribers (see above)

- Concurrences Event Materials (Click Read More below and see page’s bottom)

- Concurrences Related Articles (Click Read More below and see page’s bottom)

Check the Upcoming Conferences section for the next webinars.


SYNTHESIS

Ginger Jin moderated this session. She pointed that patent settlement between brand name and generic drug makers has been an important area of IP protection and antitrust enforcement, as highlighted by the ongoing debate about pay-for-delay agreements. When the U.S. Supreme Court issued its 2013 decision in FTC v. Actavis both sides claimed victory. Eight years later, the decision has reshaped business practice in this area.

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

Speakers

Testimonial